Inhibition of dextromethorphan metabolism by moclobemide

Psychopharmacology

Volumn 135, Issue 1, 1998, Pages 22-26

  Härtter, Sebastian ^a   Dingemanse, Jasper ^b   Baier, Dieter ^c   Ziegler, Gismar ^d   Hiemke, Christoph ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Clin Pharma Research AG   (Switzerland)

^c ROCHE INNOVATION CENTER MUNICH   (Germany)

^d Institute of Psychosomatic Research   (Germany)

Author keywords

CYP2D6; Dextromethorphan; Drug interactions; Extensive metabolizer; Moclobemide; Poor metabolizer

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 ISOENZYME; DEXTROMETHORPHAN; MOCLOBEMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; VOLUNTEER;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; AREA UNDER CURVE; BENZAMIDES; BIOTRANSFORMATION; DEXTROMETHORPHAN; DRUG INTERACTIONS; HUMANS; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITORS;

EID: 0031963544     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050481     Document Type: Article

References (22)

1. Alván G (1991) Clinical consequences of polymorphic drug oxidation. Fundam Clin Pharmacol 5:209-228
2. Benson WM, Stefko PL, Randall LO (1953) Comparative pharmacology of levorphan, racemorphan, and dextrorphan and related methyl ethers. J Pharmacol Exp Ther 109:189-200
3. Bochner F, Somogyi AA, Chen ZR (1994) Dextromethorphan metabolism in rat: interstrain differences and the fate of individually administered oxidative metabolites. Xenobiotica 24: 543-552
4. Da Prada M, Kettler R, Keller HH, Burkard WP (1990) Short-lasting and reversible inhibition of monoamine oxidase-A by moclobemide. Acta Psychiatr Scand 82 [Suppl 360]: 103-105
5. Derenne F, Joanne C, Vandel S, Bertschy G, Volmal R, Bechtel P (1989) Debrisoquine oxidative phenotyping and psychiatric drug treatment. Eur J Clin Pharmacol 36:53-58
6. Eichelbaum M, Spannbrucker N, Steincke B, Dengler JH (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic detect. Eur J Clin Pharmacol 16:183-187
7. Gonzales FJ (1992) Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 13:346-352
8. Gorski JC, Jones DR, Wrighton SA, Hall SD (1994) Characterization of dextromethorphan N-demethylation by human liver microsomes. Biochem Pharmacol 48:173-182
9. Gram LF, Brøsen K, and the Danish University Antidepresssant Group (1993) Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Br J Clin Pharmacol 35: 649-652
10. Gram LF, Guentert TW, Grange S, Viestisen K, Brøsen K (1995) Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 57:670-677
11. Guentert TW, Grange S, Bock J, Waldburger R, Birnboeck H (1995) Lack of an important influence of CYP2D6 oxidation status on the pharmacokinetics of moclobemide. Clin Pharmaø col Ther 57:151
12. Härtter S, Baier D, Dingemanse J, Ziegler G, Hiemke C (1996) Automated determination of dextromethorphan and its main metabolites in human plasma by high performance-liquid chromatography and column switching. Ther Drug Monit 18: 297-303
13. Hildebrand M, Seifert W, Reichenberger A (1989) Determination of dextromethorphan metabolizer phenotype in healthy volunteers. Eur J Clin Pharmacol 36: 315-318
14. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T (1993) CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3:197-204
15. Jauch R, Griesser E, Oesterhelt G, Arnold W, Meister W, Ziegler WH, Guentert TW (1990) Biotransformation of moclobemide in humans. Acta Psychiatr Scand 82 [Suppl 360]:87-90
16. Kerry NL, Somogyi AA, Mikus G, Bochner K (1993) Primary and secondary oxidative metabolism of dextromethorphan. Biochem Pharmacol 45:833-839
17. Kerry NL, Somogyi AA, Bochner F, Mikus G (1994) The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. Br J Clin Pharmacol 38:243-248
18. Mayersohn M, Guentert TW (1995) Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacokinet 29:292-332
19. Mortimer O, Lindstrom B, Laurell H, Bergmann U, Rane A (1989) Dextromethorphan: polymorphic serum pattern of the O-demethylated and didemethylated metabolite in man. Br J Clin Pharmacol 27:223-227
20. Schmid B, Bircher J, Preisig R, Küpfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618-624
21. Tucker GT (1994) Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol 46[Suppl 1]: 417-424
22. Von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI (1994) Cytochromes in psychopharmacology. J Clin Psychopharmacol 14:1-4